HR
ARRY

Howe & Rusling’s Array Biopharma Inc ARRY Stock Holding History

Howe & Rusling’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-127
Closed – – 1170
2016
Q2 		$0 Hold
127
– – ﹤0.01% 1083
2016
Q1 		$0 Hold
127
– – ﹤0.01% 1084
2015
Q4 		$1K Hold
127
– – ﹤0.01% 963
2015
Q3 		$1K Hold
127
– – ﹤0.01% 988
2015
Q2 		$1K Buy
+127
New +$937 ﹤0.01% 1010

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Howe & Rusling's ARRY Position: Q3 2016 in Review

Howe & Rusling sold out of Array Biopharma Inc (ARRY) in Q3 2016, closing a stake of 127 shares.

Howe & Rusling first reported a position in ARRY in Q2 2015 and held it in 5 quarters. The position peaked at $1K in Q4 2015. 169 funds tracked by Wall St. Rank hold ARRY as of Q3 2016.

  • Howe & Rusling reported no remaining Array Biopharma Inc position as of Q3 2016 after selling out during the quarter.
  • Howe & Rusling sold 127 Array Biopharma Inc shares in Q3 2016.
  • Howe & Rusling first reported a position in Array Biopharma Inc in Q2 2015 and held it in 5 quarters.
  • Howe & Rusling's Array Biopharma Inc position peaked at $1K in Q4 2015.
  • 169 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2016.

Based on Howe & Rusling's 13F filing for Q3 2016, filed 17 Oct 2016.